Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more

1901 West 47th Place, Kansas City, KS, 66205, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

45.35M

52 Wk Range

$3.20 - $7.92

Previous Close

$6.09

Open

$6.09

Volume

307,022

Day Range

$5.91 - $6.39

Enterprise Value

20.44M

Cash

6.119M

Avg Qtr Burn

-4.244M

Insider Ownership

28.16%

Institutional Own.

6.71%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CTx-1301 (dexmethylphenidate) Details Attention deficit hyperactivity disorder	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTx-1302 (dextroamphetamine) Details Attention deficit hyperactivity disorder	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTx-2103 (buspirone) Details Anxiety Disorders	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.